Ord Rosalynn L, Rodriguez Marilis, Lobo Cheryl A
a Blood-Borne Parasites; Lindsley Kimball Research Institute; New York Blood Center ; New York , NY , USA.
Hum Vaccin Immunother. 2015;11(6):1465-73. doi: 10.1080/21645515.2015.1026496.
With drug resistance to available therapeutics continuing to develop against Plasmodium falciparum malaria, the development of an effective vaccine candidate remains a major research goal. Successful interruption of invasion of parasites into erythrocytes during the blood stage of infection will prevent the severe clinical symptoms and complications associated with malaria. Previously studied blood stage antigens have highlighted the hurdles that are inherent to this life-cycle stage, namely that highly immunogenic antigens are also globally diverse, resulting in protection only against the vaccine strain, or that naturally acquired immunity to blood stage antigens do not always correlate with actual protection. The blood stage antigen reticulocyte binding homolog RH5 is essential for parasite viability, has globally limited diversity, and is associated with protection from disease. Here we summarize available information on this invasion ligand and recent findings that highlight its candidacy for inclusion in a blood-stage malaria vaccine.
随着恶性疟原虫对现有治疗药物的耐药性不断发展，开发一种有效的候选疫苗仍然是主要的研究目标。在感染的血液阶段成功阻断寄生虫侵入红细胞将预防与疟疾相关的严重临床症状和并发症。先前研究的血液阶段抗原凸显了这个生命周期阶段固有的障碍，即高免疫原性抗原在全球范围内也具有多样性，导致仅对疫苗株有保护作用，或者对血液阶段抗原的自然获得性免疫并不总是与实际保护相关。血液阶段抗原网织红细胞结合同源物RH5对寄生虫的生存至关重要，在全球范围内多样性有限，并且与疾病保护相关。在这里，我们总结了关于这种入侵配体的现有信息以及最近的发现，这些发现突出了其作为血液阶段疟疾疫苗候选物的可能性。
